Sign in
Taking peoplePhase 2

H001 capsules to prevent blood clots after total knee replacement surgery

Tests H001 capsules against enoxaparin to prevent venous thromboembolism after knee replacement.

Key facts

Who runs it
Livzon Pharmaceutical Group Inc.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
Status
Recruiting
Phase
Phase 2
People taking part
320 people, planned
Started
20 Jan 2025
Planned end
30 Jul 2025
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • H001 Capsule 200mg-qd
  • Enoxaparin Sodium Injection
  • H001 Capsule 300mg-qd
  • H001 Capsule 200mg-bid
Record updated
9 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are scheduled for a planned first knee replacement on one knee. It tests H001 capsules against enoxaparin injections to prevent blood clots in the veins after the surgery.

Age
18 to 74 years
Sex
All sexes
Disease stage
Planned first-time total knee replacement on one side (elective primary unilateral total knee arthroplasty).
Earlier treatment
No blood thinners (anticoagulants) or antiplatelet drugs in the 7 days before surgery. No long-acting NSAIDs in the 7 days or 5 half-lives before surgery, whichever is longer. No clot-dissolving treatment in the 6 months before screening.

Main reasons for not taking part

  • Pregnant or breastfeeding, or a positive pregnancy test at screening
  • Body weight under 40 kg (88 lb), or a past deep vein clot (DVT) or one found at screening
  • High bleeding risk, recent bleeding, or a past bleeding stroke
  • Recent heart attack, lung clot or major surgery, severe heart failure, or blood pressure that is not under control
  • Cancer in the past 5 years, or severe liver or kidney problems

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Patients scheduled to undergo elective primary unilateral total knee arthroplasty (TKA)
  • Aged 18-74 years (inclusive) on the day of signing the informed consent form, regardless of gender
  • Willing and able to voluntarily sign the informed consent form and comply with the study protocol
  • Women of childbearing potential or subjects whose partners are women of childbearing potential must agree to use effective contraception throughout the study period. Acceptable methods include oral, implantable, or injectable hormonal contraceptives; mechanical products (e.g., intrauterine devices, diaphragms, condoms, spermicides); abstinence; or confirmed sterilization (e.g., vasectomy, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)

Who cannot take part

  • Poorly controlled hypertension within 3 months prior to screening (defined as failure to achieve target blood pressure despite ≥3 antihypertensive medications) or systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg confirmed during screening
  • Major surgery or trauma within 3 months prior to screening, particularly involving the brain, spine, or eyes
  • Use of the following treatments:; Ongoing or recent (within 7 days pre-surgery) anticoagulant therapy (e.g., after mechanical heart valve replacement) or plans to continue such therapy during the study; Oral antiplatelet therapy (e.g., aspirin >165 mg/day, clopidogrel, ticlopidine, dipyridamole) within 7 days pre-surgery or plans to continue during the study; Long-acting NSAIDs within 7 days or 5 half-lives (whichever is longer) prior to surgery; Thrombolytic therapy for ischemic disease within 6 months prior to screening
  • Participation in another drug/device clinical trial within 1 month prior to screening or within 5 half-lives of the investigational drug (whichever is longer)
  • History of allergy to contrast agents or inability to undergo bilateral lower limb venography; history of hypersensitivity to the study drug or drugs of the same class; known allergy to enoxaparin or any component listed in the enoxaparin prescribing information
  • High bleeding risk or contraindications to enoxaparin (e.g., known or suspected heparin-induced thrombocytopenia, severe hematologic disorders, severe coagulation abnormalities)
  • History of deep vein thrombosis (DVT) or DVT confirmed during screening
  • Planned or ongoing use of epidural analgesia post-surgery; planned or ongoing use of intermittent pneumatic compression devices, electrical/mechanical muscle stimulators post-surgery; intraoperative complications (e.g., hemorrhage or severe trauma) during spinal/epidural anesthesia
  • History of malignancy within 5 years prior to screening (excluding basal cell carcinoma or Stage I squamous cell carcinoma)
  • History of drug abuse or psychiatric disorders
  • Other conditions deemed unsuitable for study participation by the investigator
  • Clinically significant medical history, including; Hemorrhagic stroke or intracranial conditions (e.g., hemorrhage, tumor, arteriovenous malformation, or aneurysm); Recurrent upper gastrointestinal or genital/urinary tract ulcers/bleeding, intraocular bleeding, or clinical bleeding within 6 months prior to screening (as judged by the investigator to increase bleeding risk); Acute hepatitis within 1 year prior to screening or persistent severe liver disease (e.g., chronic active hepatitis, cirrhosis, or chronic hepatic insufficiency); Myocardial infarction, acute coronary syndrome, viral myocarditis, pulmonary embolism, or coronary revascularization within 6 months prior to screening; transient ischemic attack or ischemic stroke; Chronic congestive heart failure with NYHA Class IV cardiac function; Severe arrhythmias requiring Class Ia or III antiarrhythmic drugs; sinus node dysfunction, Type II Mobitz or third-degree atrioventricular block without pacemaker implantation; History of QTc interval prolongation or QTc interval ≥480 ms during screening
  • Laboratory abnormalities at screening:; Total bilirubin >1.5×ULN, ALT or AST >3×ULN; Serum creatinine >1.5×ULN; chronic kidney disease with eGFR <30 mL/min/1.73 m²; Hemoglobin <100 g/L; Platelet count <100×10⁹/L; APTT, PT, or INR >ULN with clinical significance (investigator judgment)
  • Positive serum pregnancy test (hCG) during screening
  • Pregnant or breastfeeding female subjects
  • Body weight <40 kg at screening

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 74 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total Knee Arthroplasty.

The 4 groups in the trial

  • H001 Capsule 200mg-qdTreatment being tested
  • H001 Capsule 300mg-qdTreatment being tested
  • H001 Capsule 200mg-bidTreatment being tested
  • Enoxaparin Sodium InjectionExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Open-label, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of H001 Capsules in the Prevention of Venous Thromboembolism (VTE) in Subjects Undergoing Total Knee Arthroplasty
Plain-language title
H001 capsules to prevent blood clots after total knee replacement surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT06963320, who can take part
Record updated
9 May 2025